Systemic biomarkers in electronic cigarette users: Implications for noninvasive assessment of vaping-associated pulmonary injuries

ERJ Open Research

Volumn 5, Issue 4, 2019, Pages

  Singh, Kameshwar P ^a   Lawyer, Gina ^a   Muthumalage, Thivanka ^a   Maremanda, Krishna P ^a   Khan, Naushad Ahmad ^a   McDonough, Samantha R ^a   Ye, Dongxia ^a   McIntosh, Scott ^a   Rahman, Irfan ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTANE; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; CELL ADHESION MOLECULE 1; CORTICOSTEROID; FIBRINOGEN; GALECTIN 3; GAMMA INTERFERON; GELATINASE B; GRANULOCYTE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOXIN A; MALONALDEHYDE; MONOCYTE CHEMOTACTIC PROTEIN 1; NERVE GROWTH FACTOR BETA SUBUNIT; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR AA; RANTES; RESERPINE; SCATTER FACTOR; THROMBOXANE B2; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VASCULOTROPIN;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DNA DAMAGE; ENDOTHELIAL DYSFUNCTION; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; FLUOROMETRY; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; IMMUNOASSAY; INFLAMMATION; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG INJURY; MAGNETIC LUMINEX ASSAY; MALE; NON INVASIVE PROCEDURE; OXIDATIVE STRESS; PEAK EXPIRATORY FLOW; SPIROMETRY; TOXICITY; VAPING;

EID: 85078432482     PISSN: None     EISSN: 23120541     Source Type: Journal    
DOI: 10.1183/23120541.00182-2019     Document Type: Article

References (70)

1. Grana R, Benowitz N, Glantz SA. E-cigarettes: a scientific review. Circulation 2014; 129: 1972–1986.
2. Goniewicz ML, Knysak J, Gawron M, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control 2014; 23: 133–139.
3. Samburova V, Bhattarai C, Strickland M, et al. Aldehydes in exhaled breath during e-cigarette vaping: pilot study results. Toxics 2018; 6: E46.
4. Kaur G, Muthumalage T, Rahman I. Mechanisms of toxicity and biomarkers of flavoring and flavor enhancing chemicals in emerging tobacco and non-tobacco products. Toxicol Lett 2018; 288: 143–155.
5. Vansickel AR, Eissenberg T. Electronic cigarettes: effective nicotine delivery after acute administration. Nicotine Tob Res 2013; 15: 267–270.
6. Nides MA, Leischow SJ, Bhatter M, et al. Nicotine blood levels and short-term smoking reduction with an electronic nicotine delivery system. Am J Health Behav 2014; 38: 265–274.
7. Yan XS, D’Ruiz C. Effects of using electronic cigarettes on nicotine delivery and cardiovascular function in comparison with regular cigarettes. Regul Toxicol Pharmacol 2015; 71: 24–34.
8. Vlachopoulos C, Ioakeimidis N, Abdelrasoul M, et al. Electronic cigarette smoking increases aortic stiffness and blood pressure in young smokers. J Am Coll Cardiol 2016; 67: 2802–2803.
9. Qasim H, Karim ZA, Rivera JO, et al. Impact of electronic cigarettes on the cardiovascular system. J Am Heart Assoc 2017; 6: e006353.
10. Carnevale R, Sciarretta S, Violi F, et al. Acute impact of tobacco vs electronic cigarette smoking on oxidative stress and vascular function. Chest 2016; 150: 606–612.
11. Higashi Y, Noma K, Yoshizumi M, et al. Endothelial function and oxidative stress in cardiovascular diseases. Circ J 2009; 73: 411–418.
12. Antoniewicz L, Bosson JA, Kuhl J, et al. Electronic cigarettes increase endothelial progenitor cells in the blood of healthy volunteers. Atherosclerosis 2016; 255: 179–185.
13. Reidel B, Radicioni G, Clapp PW, et al. E-cigarette use causes a unique innate immune response in the lung, involving increased neutrophilic activation and altered mucin secretion. Am J Respir Crit Care Med 2018; 197: 492–501.
14. Meo SA, Ansary MA, Barayan FR, et al. Electronic cigarettes: impact on lung function and fractional exhaled nitric oxide among healthy adults. Am J Mens Health 2019; 13: 1557988318806073.
15. Shields PG, Berman M, Brasky TM, et al. A review of pulmonary toxicity of electronic cigarettes in the context of smoking: a focus on inflammation. Cancer Epidemiol Biomarkers Prev 2017; 26: 1175–1191.
16. Canistro D, Vivarelli F, Cirillo S, et al. E-cigarettes induce toxicological effects that can raise the cancer risk. Sci Rep 2017; 7: 2028.
17. Clapp PW, Jaspers I. Electronic cigarettes: their constituents and potential links to asthma. Curr Allergy Asthma Rep 2017; 17: 79.
18. Chapman DG, Casey DT, Ather JL, et al. The effect of flavored e-cigarettes on murine allergic airways disease. Sci Rep 2019; 9: 13671.
19. Liu J, Liang Q, Frost-Pineda K, et al. Relationship between biomarkers of cigarette smoke exposure and biomarkers of inflammation, oxidative stress, and platelet activation in adult cigarette smokers. Cancer Epidemiol Biomarkers Prev 2011; 20: 1760–1769.
20. Shiels MS, Katki HA, Freedman ND, et al. Cigarette smoking and variations in systemic immune and inflammation markers. J Natl Cancer Inst 2014; 106: dju294.
21. Garcia-Rio F, Miravitlles M, Soriano JB, et al. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res 2010; 11: 63.
22. Selvarajah S, Todd I, Tighe PJ, et al. Multiple circulating cytokines are coelevated in chronic obstructive pulmonary disease. Mediators Inflamm 2016; 2016: 3604842.
23. Rahman I, Morrison D, Donaldson K, et al. Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med 1996; 154: 1055–1060.
24. Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156: 341–357.
25. 2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 1995; 332: 1198–1203.
26. Pizzino G, Irrera N, Cucinotta M, et al. Oxidative stress: harms and benefits for human health. Oxid Med Cell Longev 2017; 2017: 8416763.
27. Christiani DC. Vaping-induced lung injury. N Engl J Med 2019; in press [https://doi.org/10.1056/NEJMe1912032].
28. Viswam D, Trotter S, Burge PS, et al. Respiratory failure caused by lipoid pneumonia from vaping e-cigarettes. BMJ Case Rep 2018; 2018: bcr-2018-224350.
29. Maddock SD, Cirulis MM, Callahan SJ, et al. Pulmonary lipid-laden macrophages and vaping. N Engl J Med 2019; 381: 1488–1489.
30. Schier JG, Meiman JG, Layden J, et al. Severe pulmonary disease associated with electronic-cigarette-product use – interim guidance. MMWR Morb Mortal Wkly Rep 2019; 68: 787–790.
31. Kennedy SM, Elwood RK, Wiggs BJ, et al. Increased airway mucosal permeability of smokers. Relationship to airway reactivity. Am Rev Respir Dis 1984; 129: 143–148.
32. Kinnula VL, Ilumets H, Myllarniemi M, et al. 8-Isoprostane as a marker of oxidative stress in nonsymptomatic cigarette smokers and COPD. Eur Respir J 2007; 29: 51–55.
33. Montuschi P, Collins JV, Ciabattoni G, et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000; 162: 1175–1177.
34. Czekala L, Simms L, Stevenson M, et al. Toxicological comparison of cigarette smoke and e-cigarette aerosol using a 3D in vitro human respiratory model. Regul Toxicol Pharmacol 2019; 103: 314–324.
35. Lee J, Taneja V, Vassallo R. Cigarette smoking and inflammation: cellular and molecular mechanisms. J Dent Res 2012; 91: 142–149.
36. van der Vaart H, Postma DS, Timens W, et al. Acute effects of cigarette smoke on inflammation and oxidative stress: a review. Thorax 2004; 59: 713–721.
37. Maggio M, Guralnik JM, Longo DL, et al. Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci 2006; 61: 575–584.
38. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 2014; 6: a016295.
39. Mukaida N. Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am J Physiol Lung Cell Mol Physiol 2003; 284: L566–L577.
40. Passalacqua G, Mincarini M, Colombo D, et al. IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies. Pulm Pharmacol Ther 2017; 45: 95–100.
41. H 2-type diseases. Vitam Horm 2006; 74: 479–504.
42. Mokeem SA, Alasqah MN, Michelogiannakis D, et al. Clinical and radiographic periodontal status and whole salivary cotinine, IL-1beta and IL-6 levels in cigarette-and waterpipe-smokers and E-cig users. Environ Toxicol Pharmacol 2018; 61: 38–43.
43. Rahimi S, Khosravi A, Aazami S, et al. Effect of smoking on cyanide, IL-2 and IFN-γ levels in saliva of smokers and nonsmokers. Polish Ann Med 2018; 25: 203–206.
44. Scott A, Lugg ST, Aldridge K, et al. Pro-inflammatory effects of e-cigarette vapour condensate on human alveolar macrophages. Thorax 2018; 73: 1161–1169.
45. Bozier J, Rutting S, Xenaki D, et al. Heightened response to e-cigarettes in COPD. ERJ Open Res 2019; 5: 00192-2018.
46. Lerner CA, Sundar IK, Yao H, et al. Vapors produced by electronic cigarettes and e-juices with flavorings induce toxicity, oxidative stress, and inflammatory response in lung epithelial cells and in mouse lung. PLoS One 2015; 10: e0116732.
47. Sussan TE, Gajghate S, Thimmulappa RK, et al. Exposure to electronic cigarettes impairs pulmonary anti-bacterial and anti-viral defenses in a mouse model. PLoS One 2015; 10: e0116861.
48. Husari A, Shihadeh A, Talih S, et al. Acute exposure to electronic and combustible cigarette aerosols: effects in an animal model and in human alveolar cells. Nicotine Tob Res 2016; 18: 613–619.
49. Hwang JH, Lyes M, Sladewski K, et al. Electronic cigarette inhalation alters innate immunity and airway cytokines while increasing the virulence of colonizing bacteria. J Mol Med 2016; 94: 667–679.
50. Li D, Sundar IK, McIntosh S, et al. Association of smoking and electronic cigarette use with wheezing and related respiratory symptoms in adults: cross-sectional results from the Population Assessment of Tobacco and Health (PATH) study, wave 2. Tob Control 2019; in press [https://doi.org/10.1136/tobaccocontrol-2018-054694].
51. Atkinson JJ, Lutey BA, Suzuki Y, et al. The role of matrix metalloproteinase-9 in cigarette smoke-induced emphysema. Am J Respir Crit Care Med 2011; 183: 876–884.
52. Welsh P, Whincup PH, Papacosta O, et al. Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle-aged men. QJM 2008; 101: 785–791.
53. Gilowska I, Kasper L, Bogacz K, et al. Impact of matrix metalloproteinase 9 on COPD development in Polish patients: genetic polymorphism, protein level, and their relationship with lung function. Biomed Res Int 2018; 2018: 6417415.
54. Kotteas EA, Boulas P, Gkiozos I, et al. The intercellular cell adhesion molecule-1 (ICAM-1) in lung cancer: implications for disease progression and prognosis. Anticancer Res 2014; 34: 4665–4672.
55. Prasad K, Dhar I, Caspar-Bell G. Role of advanced glycation end products and its receptors in the pathogenesis of cigarette smoke-induced cardiovascular disease. Int J Angiol 2015; 24: 75–80.
56. Iwamoto H, Gao J, Pulkkinen V, et al. Soluble receptor for advanced glycation end-products and progression of airway disease. BMC Pulm Med 2014; 14: 68.
57. Yokota C, Minematsu K, Tomii Y, et al. Low levels of plasma soluble receptor for advanced glycation end products are associated with severe leukoaraiosis in acute stroke patients. J Neurol Sci 2009; 287: 41–44.
58. Gopal P, Reynaert NL, Scheijen JL, et al. Association of plasma sRAGE, but not esRAGE with lung function impairment in COPD. Respir Res 2014; 15: 24.
59. Rabinovich RA, Miller BE, Wrobel K, et al. Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD. Eur Respir J 2016; 47: 1365–1373.
60. Luisetti M, Ma S, Iadarola P, et al. Desmosine as a biomarker of elastin degradation in COPD: current status and future directions. Eur Respir J 2008; 32: 1146–1157.
61. Chaumont M, de Becker B, Zaher W, et al. Differential effects of e-cigarette on microvascular endothelial function, arterial stiffness and oxidative stress: a randomized crossover trial. Sci Rep 2018; 8: 10378.
62. Prochaska JJ. The public health consequences of e-cigarettes: a review by the National Academies of Sciences. A call for more research, a need for regulatory action. Addiction 2019; 114: 587–589.
63. Benowitz NL, Burbank AD. Cardiovascular toxicity of nicotine: implications for electronic cigarette use. Trends Cardiovasc Med 2016; 26: 515–523.
64. Mak JC, Chan-Yeung MM, Ho SP, et al. Elevated plasma TGF-beta1 levels in patients with chronic obstructive pulmonary disease. Respir Med 2009; 103: 1083–1089.
65. Schmidt-Lucke C, Belgore F, Reinhold D, et al. Soluble vascular endothelial growth factor, soluble VEGF receptor Flt-1 and endothelial function in healthy smokers. Int J Cardiol 2005; 100: 207–212.
66. Kamizono Y, Shiga Y, Suematsu Y, et al. Impact of cigarette smoking cessation on plasma alpha-klotho levels. Medicine 2018; 97: e11947.
67. Serhan CN, Levy BD. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. J Clin Invest 2018; 128: 2657–2669.
68. Croasdell A, Thatcher TH, Kottmann RM, et al. Resolvins attenuate inflammation and promote resolution in cigarette smoke-exposed human macrophages. Am J Physiol Lung Cell Mol Physiol 2015; 309: L888–L901.
69. Tsai M, Song MA, McAndrew C, et al. Electronic versus combustible cigarette effects on inflammasome component release into human lung. Am J Respir Crit Care Med 2019; 199: 922–925.
70. McConnell R, Barrington-Trimis JL, Wang K, et al. Electronic cigarette use and respiratory symptoms in adolescents. Am J Respir Crit Care Med 2017; 195: 1043–1049.